Altogen Laboratory Testing of Known Compounds for Cancer Treatment Efficacy

Sodium dichloroacetate (DCA) has been investigated as a novel cancer therapy since 2007 when Bonnet et al published research study demonstrating the efficacy of DCA in treating human cancers by inhibition of mitochondrial pyruvate dehydrogenase kinase (PDK). Altogen Labs, an Austin-based biotechnology and preclinical research company, performed an independent study exploring potential novel and accessible cancer treatment options based on structurally modified DCA analogues. The results of the study identified two cationic dichloric compounds, referred to as DCAH and DCMAH, as potential candidates for further investigation. The study, recently published in Cancer Biology & Therapy, demonstrated in vivo efficacy of structurally modified analogs (DCAH and DCMAH) in U87 human glioblastoma xenograft model. The anti-tumor effect is comparable to both DCA and the well-known chemotherapy drug bevacizumab used for treatment of glioblastoma.

Dr. Dmitriy Ovcharenko, Altogen Labs corresponding author of the article, described that this work was performed in collaboration with National Cancer Institute’s Developmental Therapeutics Program (NIH). Of the three primary characteristics varied in our test compounds (charge/polarity, electron distribution, and spatial arrangement), reversing the charge compared with DCA produced the largest effect on tumor viability. While these dichloric compounds were initially investigated due to their similarity to dichloroacetate (DCA), immunoblotting results suggested a cellular pathway effect for DCAH and DCMAH independent from that of DCA. According to Altogen Labs’ senior scientist Dr. Catrina Chitjian, this work suggests the clinical potential for DCAH and DCMAH as minimally toxic anti-cancer drugs and demonstrates the importance of additional studies. Interestingly, DCAH and DCMAH are simple small molecules traditionally used as building blocks for organic chemistry synthesis, which is promising for potentially inexpensive mass production.

About Altogen Labs

Altogen Labs is a GLP-compliant preclinical contract research laboratory dedicated to providing cutting edge research services in the fields of cancer, biomedical and pharmaceutical research. Company developed and validated over 120 xenograft models supplemented by both in vitro and in vivo efficacy assays, toxicology, gene expression, and gene function analyses. Altogen Labs provides wide range of biology CRO services including tox/pharm assays, biodistribution, and stable cell line development.


Alex Fanelli, PhD

Altogen Labs

11200 Manchaca Road, Suite 203

Austin TX 78748 USA

Tel. 512-433-6177

Characterizing Novel Inhibitor Activity

Publication [Download PDF]: Alexandra Tyulyandina, Daniel Harrison, Wei Yin, et al.  Invest New Drugs 35: 127–133. doi: 10.1007/s10637-016-0400-5 Based on data from 2013-2015, about 38% of the population will be diagnosed with some type of cancer during their lifetime, and there is an ongoing need for improved treatment techniques. Some chemotherapy agents are specific to… Continue Reading

Altogen Xenograft Model in a KRAS Pancreatic Adenocarcinoma Study

Publication [Download PDF]: KRAS mutant allele-specific expressionknockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex by Donald D. Rao et al. PLOS ONE Pancreatic cancer is notorious for its poor prognosis caused by early metastasis potential. While cancer biology has obtained a deeper understanding of biochemical, micro-environmental, genetic and epigenetic occurrences in… Continue Reading

Altogen Labs in Therapeutic Oligonucleotide Patent Application

Dnai for the modulation of genes Aberrant gene expression, for example overexpression or expression of mutant genes and proteins, is the root cause of many diseases. Cancer is a result of aberrant cellular signaling that causes uncontrolled growth and proliferation; as a complex disease, combination proteins involving angiogenesis, epithelial to mesenchymal transition, tumor suppression, cell… Continue Reading

Acute Myeloid Leukemia (AML) Research Study

Publication [Download PDF]: MicroRNA29a regulates the expression of the nuclear oncogene Ski. Blood. 118(7):1899-902. doi: 10.1182/blood-2010-09-306258 Acute myeloid leukemia (AML) is a rapidly progressing cancer characterized by the abnormal buildup of myeloid cells that interfere with normal blood cell (red, white and platelet) function. There are certain genetic markers, for example monosomy 7 (–7) and… Continue Reading

Altogen Labs offers in vivo imaging services for drug development and biodistribution studies: Orthotopic glioma xenograft model

Altogen Labs provides in vivo imaging services for drug development and biodistribution studies: U87 orthotopic glioma xenograft animal model study  by Altogen Labs, 11200 Manchaca Rd, Suite 203 Austin TX 78748 USA Download full text PDF:  Introduction In vivo imaging has emerged as a critical tool in visualization in preclinical research studies related to the development… Continue Reading

Altogen Labs in the Investigation of miRNA expression of Acute Myeloid Leukemia

Publication [Download PDF]: Dmitriy Ovcharenko, Friedrich Stolzel, David Poitz, Fernando Fierro, Markus Schaich, Andreas Neubauer, Kevin Kelnar, Timothy Davison, Carsten Muller-Tidow, Christian Thiede, Martin Bornhauser, Gerhard Ehninger, David Brown, and Thomas Illmer. Experimental Hematology 2011; 39:1030–1042 Acute myeloid leukemia (AML) is a cancer that affects hematopoietic stem cells and often results in the accumulation of… Continue Reading

Alofanib Preclinical Research Study

Publication [Download PDF]: Tyulyandina, A., Harrison, D., Yin, W. et al. Invest New Drugs (2017) 35: 127. Ovarian cancer is notorious for its poor prognosis; five-year survival rates for are 40% and 18% for stages III and IV, respectively. Ovarian cancer classifications are defined by the origin cell types and include papillary serous histology,… Continue Reading

Xenograft Models for Preclinical Research: From Translational Studies to Clinical Trials

AUSTIN, TX, December 17, 2018 Altogen Labs, a biotechnology laboratory focused on the development of innovative cancer therapeutics, today announced the addition of new CDX models (MDA-MB-157, MDA-MB-453, U87, and OVCAR-3). The addition of these xenograft models further increases Altogen Labs’ product line in breast and ovarian cancer, as well as glioblastoma to 89 CDX,… Continue Reading

Medical Discovery and Innovation: Altogen Labs Preclinical CRO Services

Altogen Labs Preclinical CRO Services Altogen Labs (, an Austin, TX based contract research organization (CRO) offers preclinical laboratory services to pharmaceutical, biotechnology, and academic researchers worldwide to support and accelerate medical discovery and research studies. Our Good Laboratory Practice (GLP)-compliant laboratory located at 11200 Manchaca Rd, Suite 203, Austin TX offers services for drug toxicology, drug efficacy, drug… Continue Reading